Tickertape - Financial freedom begins here

The offer was triggered after Frontier Warehousing entered into a share purchase agreement with Kesoram's promoter-group entities to acquire 13,29,69,279 equity shares at Rs 4 per share. This block represents 42.8% of Kesoram's voting share capital. Earlier this year, UltraTech Cement announced a 1:52 share swap ratio for its acquisition of Kesoram Industries, issuing one UltraTech share for every 52 held by Kesoram shareholders. The scheme took effect on 1 March 2025, formalising the transfer of Kesoram's cement business to UltraTech under a composite arrangement dated 1 April 2024. Post demerger, Kesoram ceased standalone manufacturing operations and now focuses on its remaining businesses, including rayon, transparent paper and chemicals, housed under its wholly owned subsidiary Cygnet Industries. Kesoram Rayon manufactures rayon, transparent paper and filament yarn. On a consolidated basis, Kesoram Industries reported net loss of Rs 25.87 crore in Q2 September 2025 as against net loss of Rs 69.92 crore in Q2 September 2024. Net sales declined 6.03% YoY to Rs 55.17 crore in Q2 September 2025. Powered by Capital Market - Live

The product is a generic equivalent of Novartis Pharmaceuticals' Mayzent Tablets and is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, in adults. Lupin said the tablets will be manufactured at its Pithampur facility in India. According to IQVIA MAT October 2025 data, Siponimod Tablets (reference listed drug Mayzent) recorded annual U.S. sales of USD 195 million. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin reported a 73.33% surge in consolidated net profit to Rs 1,477.92 crore in Q2 FY26 as against Rs 852.63 crore posted in Q2 FY25. Revenue from operations jumped 24.27% year-on-year to Rs 6,831.43 crore in the quarter ended 30 September 2025. The counter shed 0.21% to Rs 2,087.55 on the BSE. Powered by Capital Market - Live

The Reserve Bank on Thursday issued clarification regarding prudential treatment of exposures of foreign bank branches operating in India to their group entities, along with host of amendments to various other regulations. The amendments to Large Exposures Framework (LEF) and Intragroup Transactions and Exposures also suggests for certain methodological aspects relating to calculation of LEF and intragroup transactions and exposures (ITE). It further said banks shall have policies on concentration risk management of their exposures towards a single counterparty, groups of interconnected counterparties, specific sectors of the economy as also systems to monitor and address the risks emanating to them from their exposures to ultra-large borrowers. Powered by Capital Market - Live